Like what you've read?

On Line Opinion is the only Australian site where you get all sides of the story. We don't
charge, but we need your support. Here�s how you can help.

  • Advertise

    We have a monthly audience of 70,000 and advertising packages from $200 a month.

  • Volunteer

    We always need commissioning editors and sub-editors.

  • Contribute

    Got something to say? Submit an essay.


 The National Forum   Donate   Your Account   On Line Opinion   Forum   Blogs   Polling   About   
On Line Opinion logo ON LINE OPINION - Australia's e-journal of social and political debate

Subscribe!
Subscribe





On Line Opinion is a not-for-profit publication and relies on the generosity of its sponsors, editors and contributors. If you would like to help, contact us.
___________

Syndicate
RSS/XML


RSS 2.0

TRIPS: protecting intellectual property or putting profits before people?

By Louise Sylvan - posted Sunday, 15 April 2001


Who will win?

Consumers International, the umbrella body of the world’s consumer organisations, in a position paper published before the Seattle WTO Ministerial Conference, stated, "Public health measures are threatened by the Trade Related Intellectual Property Rights (TRIPS) Agreement and called on the WTO members:

  • To reaffirm the primacy of public health interests over commercial consideration; and
  • To actively support the flexibility allowed in the TRIPS Agreement to enable access to essential drugs."
Advertisement

Many people would argue that the monopoly and intellectual property rights given to pharmaceutical companies has gone much too far – now putting profit well before people.

There are good reasons for wanting to ensure that pharmaceutical companies do have profits and resources available – they engage in much of the research that develops new products (although a lot of that money is public money as well which should be taken into account). Nor is it a satisfactory argument - in fact it’s quite perverse - to argue that giving manufacturers monopoly rights to recoup some of their R & D costs can be done at the cost of denying access to drugs to millions of people. Better solutions than this need to be found. The pharmaceutical manufacturers have done no good to their public image in suing South Africa - and signalling clearly to world’s consumers that their bottom lines matter more to them than anything else.

More information on this issue can be found by accessing the Consumers International site (www.consumersinternational.org), the Public Citizen site which works extensively on this issue (www.cptech.org), and the site of Medicins Sans Frontieres (www.msf.org).

  1. Pages:
  2. 1
  3. Page 2
  4. All


Discuss in our Forums

See what other readers are saying about this article!

Click here to read & post comments.

Share this:
reddit this reddit thisbookmark with del.icio.us Del.icio.usdigg thisseed newsvineSeed NewsvineStumbleUpon StumbleUponsubmit to propellerkwoff it

About the Author

Louise Sylvan is Chief Executive of the Australian Consumers' Association - CHOICE.

Other articles by this Author

All articles by Louise Sylvan
Related Links
Australian Consumer's Association
Consumers International
Photo of Louise Sylvan
Article Tools
Comment Comments
Print Printable version
Subscribe Subscribe
Email Email a friend
Advertisement

About Us Search Discuss Feedback Legals Privacy